(Q34967044)

5 August 2017

1 reference

title

Therapeutic drug monitoring in the treatment of tuberculosis (English)

1 reference

5 August 2017

0 references

Charles A Peloquin

1

1 reference

5 August 2017

publication date

1 January 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

62

1 reference

5 August 2017

issue

15

1 reference

5 August 2017

page(s)

2169-2183

1 reference

Rifampin and rifabutin drug interactions: an update

5 August 2017

cites work

1 reference

12 December 2020

Two three-month treatment regimens for pulmonary tuberculosis

1 reference

12 December 2020

Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids

1 reference

12 December 2020

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

1 reference

12 December 2020

A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association

1 reference

12 December 2020

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics

1 reference

12 December 2020

Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention

1 reference

12 December 2020

Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids

1 reference

12 December 2020

Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease

1 reference

12 December 2020

Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids

1 reference

12 December 2020

The pharmacokinetics of oral rifampicin in AIDS patients

1 reference

12 December 2020

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

1 reference

12 December 2020

Pharmacokinetic evaluation of para-aminosalicylic acid granules.

1 reference

12 December 2020

Increased incidence of tuberculosis in patients undergoing hemodialysis

1 reference

12 December 2020

Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection

1 reference

12 December 2020

Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy

1 reference

12 December 2020

Therapeutic drug monitoring in HIV infection: current status and future directions

1 reference

12 December 2020

Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes

1 reference

12 December 2020

The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol

1 reference

12 December 2020

The clinical pharmacokinetics of levofloxacin

1 reference

12 December 2020

1 reference

12 December 2020

Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis

1 reference

12 December 2020

Basic Mechanisms of Chemotherapy

1 reference

12 December 2020

Role of individual drugs in the chemotherapy of tuberculosis

1 reference

12 December 2020

An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase

1 reference

12 December 2020

Adverse effects of antituberculosis drugs

1 reference

12 December 2020

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

1 reference

12 December 2020

Rifapentine: its role in the treatment of tuberculosis

1 reference

12 December 2020

Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids.

1 reference

12 December 2020

Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients

1 reference

12 December 2020

Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection

1 reference

12 December 2020

The role of fluoroquinolones in tuberculosis today

1 reference

12 December 2020

Tuberculosis drug serum levels

1 reference

12 December 2020

Malabsorption and mucosal abnormalities of the small intestine in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention

1 reference

12 December 2020

Low antituberculosis drug concentrations in patients with AIDS.

1 reference

12 December 2020

Once-daily and twice-daily dosing of p-aminosalicylic acid granules

1 reference

12 December 2020

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

1 reference

12 December 2020

Risk of tuberculosis in dialysis patients: a population-based study

1 reference

12 December 2020

Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea

1 reference

12 December 2020

Pharmacological issues in the treatment of tuberculosis

1 reference

12 December 2020

Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids

1 reference

12 December 2020

Rifampicin raw material characteristics and their effect on bioavailability

1 reference

12 December 2020

A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis

1 reference

12 December 2020

Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.

1 reference

12 December 2020

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

1 reference

12 December 2020

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis

1 reference

12 December 2020

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

1 reference

12 December 2020

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

1 reference

12 December 2020

The molecular basis of isoniazid resistance in Mycobacterium tuberculosis

1 reference

12 December 2020

Using therapeutic drug monitoring to dose the antimycobacterial drugs

1 reference

12 December 2020

Enteropathy associated with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption

1 reference

12 December 2020

1 reference

12 December 2020

Tuberculosis: latency and reactivation

1 reference

12 December 2020

Serum concentrations of the antimycobacterial drugs

1 reference

12 December 2020

The latent tuberculosis bacillus (I'll let you know if I ever meet one)

1 reference

12 December 2020

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

12 December 2020

Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis

1 reference

12 December 2020

The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.

1 reference

12 December 2020

Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis

1 reference

12 December 2020

Development of rifapentine: the way ahead

1 reference

12 December 2020

Pharmacokinetics and Metabolism of Rifampin in Humans

1 reference

12 December 2020

Therapeutic drug monitoring in antituberculosis chemotherapy

1 reference

12 December 2020

Rekindling old controversy on elusive lair of latent tuberculosis

1 reference

12 December 2020

National surveillance of dialysis associated diseases in the United States, 1995

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

1 reference

12 December 2020

Tuberculosis in renal failure: a high incidence in patients born in the Third World

1 reference

12 December 2020

Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection.

1 reference

12 December 2020

Malabsorption of antimycobacterial medications

1 reference

12 December 2020

Clinical pharmacokinetics of the antituberculosis drugs

1 reference

12 December 2020

Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997.

1 reference

12 December 2020

Drug malabsorption and resistant tuberculosis in HIV-infected patients.

1 reference

12 December 2020

Goal-oriented, model-based drug regimens: setting individualized goals for each patient

1 reference

12 December 2020

Malabsorption of antituberculosis medications by a patient with AIDS

1 reference

12 December 2020

AIDS and TB drug absorption

1 reference

12 December 2020

Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors

1 reference

12 December 2020

Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions

1 reference

12 December 2020

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

1 reference

12 December 2020

Does AIDS impair the absorption of antituberculosis agents?

1 reference

12 December 2020

10.2165/00003495-200262150-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1019504416

0 references

1 reference